Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Balanol Analog 1 is a synthetic small molecule derivative of balanol, a fungal metabolite known for its potent inhibition of serine/threonine protein kinases. This analog has been specifically designed to enhance selectivity and potency against cyclic adenosine monophosphate-dependent protein kinase (PKA) over calcium- and phospholipid-dependent protein kinase (PKC). Structural studies show that it binds to the catalytic domain of PKA, stabilizing an intermediate conformation of the Gly-rich loop and disengaging key phosphoryl transfer residues. The compound acts as a competitive inhibitor at the ATP-binding site of these kinases. Its chemical formula is C20H22N2O5[2][3][4][5]. It remains an experimental drug candidate with no approved clinical indications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on balanol analog 1.